A combined immunosuppressive treatment regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide was effective in a Japanese cohort of 29 patients with anti-melanoma differentiation-associated gene 5 (MDA5)+ dermatomyositis-associated interstitial lung disease (ILD) in a prospective study. The 6-month survival of patients receiving combined immunosuppression was higher than that of a historical cohort of 15 patients who received step-up therapy of high-dose glucocorticoids with additional immunosuppressants (89% versus 33%, respectively).
References
Original article
Tsuji, H. et al. A multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. https://doi.org/10.1002/art.41105 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Combined immunosuppression for ILD in myositis. Nat Rev Rheumatol 15, 698 (2019). https://doi.org/10.1038/s41584-019-0328-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0328-1
